Dupilumab Improves Daily Symptom Burden in Adult Patients with Prurigo Nodularis: Post Hoc Analysis from LIBERTY PN-PRIME and PRIME2 Studies

Key Points

• To assess the efficacy of dupilumab in reducing daily symptom burden in patients with prurigo nodularis.
• Post hoc analysis of LIBERTY PN-PRIME and PRIME2 studies
• Comparison between dupilumab and placebo groups
• Evaluation of symptom improvement in itch, skin pain, and sleep disturbance.
• Patients on dupilumab experienced greater improvement in daily symptom burden (DSB)
• Significant reductions in itch, skin pain, and sleep disturbances compared to placebo.